Zonegran
ApprovedSmall molecule
Mylan Pharmaceuticals IncZonegran is one of 99 small molecule programs targeting Eating Disorder. It is currently in Approved.
3
Indications
10
Total Trials
0
Active Trials
98
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
109 competitors in Seizure
#DrugCompanyPhaseTrials
1Briviact
UCBPhase 3
Afinitor
NovartisPhase 3
Fintepla
IImmedica Pharma AB
Phase 3
E2007
EisaiPhase 3
Ativan
BBausch Health Americas, Inc.
Phase 3
Epsom Salt
FFresenius Kabi Oncology Ltd.
Phase 3
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
SPM 929
UCBPhase 3
Valproate Sodium
SanofiPhase 3
Zonegran
Mylan Pharmaceuticals IncApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Seizure2 trials
Parkinson's Disease1 trial
4 more indications
Fasting Conditions1 trial
Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions
Completed·—·Phase 1·NCT01161966·26 enrolled
Labor1 trial
Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions
Completed·—·Phase 1·NCT01161979·26 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zonegran. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company